The rising incidence of obesity and related disorders such as diabetes and heart disease has focused considerable attention on the discovery of new therapeutics. One promising approach has been to increase the number or activity of brown-like adipocytes in white adipose depots, as this has been shown to prevent diet-induced obesity and reduce the incidence and severity of type 2 diabetes. Thus, the conversion of fat-storing cells into metabolically active thermogenic cells has become an appealing therapeutic strategy to combat obesity. Here, we report a screening platform for the identification of small molecules capable of promoting a white-to-brown metabolic conversion in human adipocytes. We identified two inhibitors of Janus kinase (JAK) activity with no precedent in adipose tissue biology that stably confer brown-like metabolic activity to white adipocytes. Importantly, these metabolically converted adipocytes exhibit elevated UCP1 expression and increased mitochondrial activity. We further found that repression of interferon signalling and activation of hedgehog signalling in JAK-inactivated adipocytes contributes to the metabolic conversion observed in these cells. Our findings highlight a previously unknown role for the JAK-STAT pathway in the control of adipocyte function and establish a platform to identify compounds for the treatment of obesity.
Mammals possess two distinct types of adipose tissue: white and brown fat. White adipose tissue (WAT) stores excess energy and has a number of endocrine functions such as regulating satiety through leptin secretion. In contrast, brown adipose tissue (BAT) maintains body temperature through non-shivering thermogenesis. BAT releases energy in the form of heat by uncoupling the respiratory chain through uncoupling protein 1 (UCP1). In addition to thermogenesis, BAT activation in rodents accelerated plasma clearance of triglycerides, ameliorated insulin resistance and protected against obesity 1, 2 . Recently, PET/CT (positron emission tomography-computed tomography) imaging revealed adipose tissue with thermogenic activity and UCP1 expression in human adults 3 . These studies also found that BAT is inversely associated with adiposity, high body mass index and hyperglycemia. On the basis of these findings, there has been an increased interest in BAT as a therapeutic target to treat metabolic disorders.
Mouse studies have reported the emergence of UCP1-expressing cells in WAT on cold exposure, β-adrenergic stimulation and peroxisome proliferator-activated receptor gamma (PPARG) activation [4] [5] [6] [7] [8] [9] [10] , a phenomenon referred to as browning. These brownlike cells arise from the recruitment of specific precursor cells 11 and/or the conversion of white into brown-like cells 12 . Two human trials have also demonstrated de novo generation of brown adipocytes on cold acclimation combined with increased non-shivering thermogenesis and decreased body fat mass 13, 14 . These studies suggest that identifying inducers of browning in humans may ameliorate obesity-related diseases. To this end, we established a screening platform to discover small molecules capable of promoting white-tobrown metabolic conversion in human adipocytes and identified JAK inhibitors as molecules with browning potential. In addition, we show that human pluripotent stem cell (PSC)-derived adipocytes provide a scalable, robust and reliable cell model for adipocyte browning studies, compound screening and drug discovery.
RESULTS

A screening platform for adipocyte browning identifies inducers of UCP1
We used a human PSC-derived adipocyte model to study the pharmacological conversion of white to brown-like adipocytes. In this approach, adipocytes are obtained through the inducible expression of transcription factors in PSC-derived mesenchymal progenitor P D E 3 i P D E 3 i -2 P P A R d -a g P P A R a / g -a g -3 P P A R a / g -a g -2 P P A R a / g -a g P P A R a -a g T H cells (MPCs) and the addition of an adipogenic cocktail to the media 15 . Inducible expression of peroxisome proliferator-activated receptor gamma2 (PPARG2) alone or a combination of PPARG2, CCAAT/enhancer-binding protein beta (CEBPB) and PR domain containing 16 (PRDM16) drives cell differentiation towards the white (PSC-WA) or brown (PSC-BA) lineage respectively 15 . We reasoned that CEBPB and PRDM16 could be replaced by small molecules to direct PPARG2-expressing MPCs towards a brown-like phenotype (Fig. 1a) . We monitored the responsiveness of PSC-WAs to known modulators of UCP1 expression 16 and observed upregulation of UCP1 messenger RNA levels on treatment with forskolin (FSK), 3-isobutyl-1-methylxanthine (IBMX), rosiglitazone and bone morphogenic protein 7 (BMP7), validating the use of PSC-WAs for browning assays ( Supplementary Fig. 1 ).
Using this model we established a screening assay for assessing the conversion of white to brown-like adipocytes (Fig. 1b) . A focused library of 867 small molecules that has a large degree of activity annotation, facilitating deconvolution of mechanism of action, was applied at day 7, when cells are differentiating and will adopt a white phenotype if no additional stimulus is applied. Adipocytes were exposed to compounds for 7 days and collected at day 14 for analysis. As a browning index, UCP1 expression was monitored by UCP1 mRNA capture plates followed by branched DNA (bDNA) amplification. Expression of fatty acid binding protein 4 (FABP4), an adipocytespecific gene, served as an internal control to eliminate anti-and pro-adipogenic compounds not specific to UCP1, such as the PPARG agonist rosiglitazone (Fig. 1c, red dot) . Out of 135 UCP1 inducers (see Methods for statistical analysis), 52 compounds induced both UCP1 and FABP4 levels (Fig. 1c, blue dots) . Among the 83 compounds that induced UCP1 specifically (Fig. 1c, green dots) , compounds that induced UCP1 at least twofold were selected as browning hits and compared with rosiglitazone-like compounds in an independent experiment ( Fig. 1d and Supplementary Table 1) . UCP1 induction by thyroid hormone receptor beta (THRB) agonists and phosphodiesterase enzyme 3 (PDE3) inhibitors is in accordance with previously reported upregulation of UCP1 promoter activity by thyroid hormone and cyclic AMP (refs 17-20) . Of particular interest, three annotated inhibitors of spleen tyrosine kinase (SYK) and two inhibitors of Janus kinase 3 (JAK3) showed the highest UCP1/FABP4 ratio. JAK3 and SYK are best characterized for their role in immune cells development and physiology and as mediators of pro-inflammatory pathways 21 . Recently, the JAK-STAT pathway was found to modulate early adipogenesis upstream of PPARG but little evidence supported a role in adipose tissue remodelling and thermogenicity 22 .
A subset of UCP1-inducers modulate adipocyte lipid droplet morphology
White adipocytes have a single or a few large lipid droplets, whereas the brown adipocytes contain multiple small lipid droplets. We exploited this morphological difference to evaluate the browning effects of newly identified UCP1-inducer compounds. Following treatment of PSC-WAs with selected compounds (Fig. 1b) , we used fluorescent dyes to mark nuclei and lipid droplets, and performed high-content imaging to quantify the number and size of lipid droplets per cell. After 7 days of treatment with selected JAK3 and SYK inhibitors, we observed changes in lipid droplet morphology that are typical of brown-like adipocytes (Fig. 2a) . In contrast, a THRB agonist was inert in this assay despite elevation of UCP1 expression ( Fig. 1d and Fig. 2a) . We determined the lipid area of small (<1,070 µm 2 ) and large (>1,070 µm 2 ) droplets per well (Fig. 2b , curve graphs) and used the ratio small/large droplet area as a 'brown-like lipid index' for each compound, as exemplified in Fig. 2c for dimethylsulphoxide (DMSO), JAK3 inhibitor, SYK inhibitor and THRB agonist. A total of 39 compounds that induced UCP1 or exhibited visible effects on lipid morphology during the browning screen were thereby quantified and ascribed a brown-like lipid index (Fig. 2d, y axis) . When the two browning indices were taken into account, that is, UCP1/FABP4 and lipid droplet morphology, JAK3 and SYK inhibitors were the most potent browning compounds from our screen (Fig. 2d ). In addition, this analysis revealed that brown-like lipid morphology was poorly correlated with elevated UCP1 expression, indicating that quantification of lipid droplet size is not a suitable phenotypic readout for adipocyte browning, at least in our system.
Validation of tofacitinib and R406 browning compounds in primary adipocytes
As model browning compounds, we selected the JAK3 inhibitor tofacitinib and the SYK inhibitor R406 for their potency in our browning assay and for their clinical relevance ( Supplementary Fig. 3 ). We examined the dose-response for tofacitinib and R406 in PSCWAs and found that the UCP1/FABP4 ratio reaches a plateau at 2 µM for tofacitinib and 1 µM for R406 (Fig. 3a) . Graphical representation of UCP1 and FABP4 normalized to a housekeeping gene revealed a UCP1-specific effect of tofacitinib, whereas R406 induced both UCP1 and FABP4 expression when dosed above 1 µM (Fig. 3a) . We confirmed that tofacitinib-and R406-mediated increases in UCP1 mRNA levels translated into accumulation of UCP1 protein (Fig. 3b ) and observed concomitant elevation in PRDM16 protein (Fig. 3b) . Importantly, we validated the effects of tofacitinib and R406 on UCP1 and FABP4 expression in lentiviral-free, human primary adipose tissue-derived stromal cells (ADSCs) differentiated according to standard procedures (Fig. 3c ). Tofacitinib and R406 also caused the emergence of brown-like lipid droplet morphologies in ADSCderived adipocyte cultures and seemed superior to BMP7 in this assay (Fig. 3d) . Finally, we subjected mouse white adipose tissue explants to increasing doses of tofacitinib and R406 and observed upregulation of UCP1 expression in explants of subcutaneous, but not visceral, origin ( Fig. 3e and Supplementary Fig. 4 ).
Tofacitinib and R406 block the JAK-STAT1/3 pathway during adipocyte browning
Tofacitinib is a potent inhibitor of signalling through JAK1 and JAK3 with 5-100-fold selectivity over JAK2 in cell-based assays 23, 24 . R406 is described as a potent and specific SYK inhibitor, but also targets JAKs, c-kit, Lck and FLT3 when profiled at 2 µM (ref. 25) . We sought to determine the pharmacological signature of tofacitinib and R406 in human adipocytes where target abundance and signalling activity might differ from immune cells. First we used RNA sequencing (RNA-seq) analysis of PSC-WAs to evaluate the abundance of known targets of tofacitinib and R406. JAK1 was the most abundantly expressed member of the JAK family, followed by Tyk2, JAK2 and JAK3 (Fig. 4a) . The abundance of SYK, c-kit, Lck and FLT3 was below statistical significance suggesting that R406 may exert its browning effect through JAK inhibition. of n = 3 biological replicates and differences from DMSO are significant for * P < 0.005. P values were calculated using the two-tailed paired Student's ttest. (h) Tofacitinib (tofa.) synergizes with THRB agonist (right panel) but not with ruxolitinib (Ruxo., left panel) during adipocyte browning. Values are mean ± s.d. of n = 3 biological replicates and differences from DMSO are significant for * P < 0.005. P values were calculated using the twotailed paired Student's t-test. Uncropped images of blots are shown in Supplementary Fig. 8 .
To profile possible downstream targets, PSC-WAs were treated with tofacitinib and R406 at the determined 'browning dose' (2 and 1 µM, respectively) for 20 min and screened by reverse-phase protein array (RPPA) covering 51 different phospho-isoforms. RPPA analysis revealed STAT3 as the main downstream target for both tofacitinib and R406 ( Supplementary Fig. 5 ). Whereas the effect of tofacitinib was restricted to STAT3 in the RPPA panel, R406 had additional downstream targets including AKT, EGFR and ERK1/2 ( Supplementary Fig. 5 ). We further investigated the effect of tofacitinib and R406 on JAK-STAT, AKT and ERK1/2 pathways by immunoblot analysis. As shown in Fig. 4b , tofacitinib and R406 blocked tyrosine phosphorylation of STAT1 and STAT3 after 20 min, an effect that is exacerbated on 7 days of treatment. In a dose-response experiment, the gradual increase in UCP1 levels negatively correlated with STAT3 phosphorylation (Fig. 4c ). Noticeably, STAT1 protein level decreased after treatment with tofacitinib and R406. Tofacitinib had no effect on AKT and MAPKs, whereas R406 significantly decreased the phosphorylation level of AKT, ERK1 and ERK2 (Fig. 4b) . AKT phosphorylation was restored at day 7, suggesting an adaptive response to maintain adipocyte homeostasis and insulin signalling. Phospho-STAT5 was undetectable in our assay and p38 and JNKs were unaltered at both times. Thus, JAK inhibitors probably change UCP1 expression through a different route than the cAMP-p38 pathway downstream of β3-adrenergic stimulation 26, 27 . Tumour necrosis factor alpha (TNF-α) represses UCP1 expression in brown adipocytes 28 , an effect also observed in PSC-WAs (Fig. 4d) . As TNF-α can signal through JAK-STAT and ERK pathways, we tested the ability of tofacitinib and R406 to antagonize TNF-α repression of UCP1 expression. Tofacitinib and R406 partially and fully restored UCP1 levels respectively, in agreement with the JAK-STAT-specific and JAK-STAT-ERK1/2 effects of each compound (Fig. 4b) . In addition, the combination of tofacitinib and R406 was not superior to R406 alone in increasing UCP1 expression (Fig. 4e) , supporting evidence that tofacitinib and R406 functionally overlap.
Finally, we tested ruxolitinib, a JAK1/2 inhibitor, and observed upregulation of UCP1 expression without significant regulation of FABP4 with concomitant inhibition of STAT1/3 phosphorylation (Fig. 4f) . Three other JAK1/2 inhibitors, AZD1480, CYT387 and baricitinib, also showed upregulation of UCP1 expression (Fig. 4g) . A combination of tofacitinib and ruxolitinib did not further increase UCP1 expression (Fig. 4h, left panel) , unlike a combination of tofacitinib with a THRB agonist (Fig. 4h, right panel) . Together, the data highlight a central role for the JAK1/2-STAT1/3 pathway in UCP1 expression in adipocytes.
Progressive and stable conversion of adipocytes by JAK inhibition
Molecules that increase UCP1 expression by directly activating the UCP1 promoter 26 may not be suitable for in vivo induction of browning or therapeutically useful to combat obesity. Alternative Values are mean ± s.e.m. of n = 3 biological replicates and differences from DMSO are significant for * P < 0.05. P values were calculated using the two-tailed paired Student's t-test. Uncropped images of blots are shown in Supplementary Fig. 8 .
mechanisms of browning such as adipocyte metabolic remodelling are needed, and our screening platform was designed for this purpose. We examined the kinetics of tofacitinib-and R406-mediated browning in comparison with THRB agonist, which also ranked in the top-10 best UCP1 inducers but failed to modify lipid droplet morphology (Figs 1d  and 2 ). The UCP1 promoter contains a thyroid hormone responsive element 20 and as expected, a THRB agonist rapidly increased UCP1 levels (Fig. 5a ). In contrast, UCP1 mRNA levels increased more slowly and progressively in tofacitinib-and R406-treated adipocytes (Fig. 5a) , consistent with remodelling of cellular metabolism rather than direct modulation of UCP1 promoter activity.
If a stable white to brown-like conversion is achieved through JAK inhibition, the brown-like phenotype should persist on removal of tofacitinib and R406. To test this, we selected 9 inducers of UCP1 mRNA levels from the original screen and treated PSC-WAs with each compound for 7 days, washed them with compound-free medium, and maintained them in compound-free medium for an additional 14 day-period (Fig. 5b) . Remarkably, all cells pre-treated with JAK inhibitors exhibited high levels of UCP1 mRNA and reduced lipid droplet size at day 28 compared with DMSO-treated cells whereas all other compounds lost their browning effect after washout (Fig. 5b,c) . Finally, we repeated the washout experiment with tofacitinib and R406 and added TNF-α at day 26, 48 h before cells collection. Even in the absence of compounds, adipocytes pre-treated with tofacitinib and R406 maintained a higher level of UCP1 when challenged with TNF-α (Fig. 5d) . Together, these results indicate that JAK inhibition leads to the stable acquisition of brown-like metabolic properties in human adipocytes.
JAK-inactivated adipocytes acquire a brown-like metabolic program
Brown adipocytes are characterized by high mitochondrial content as well as high metabolic activity 1 . Mitochondrial content was assessed by determining the ratio of subunit I of Complex IV of n = 3 biological replicates and differences from DMSO are significant for * P < 0.05 and * * P < 0.01. P values were calculated using the two-tailed paired Student's t-test.
(COX-I), which is mitochondrial DNA-encoded, to subunit A of the succinate dehydrogenase complex (SDH-A), which is nuclear DNA-encoded. Quantification of COX-1 and SDH-A immunoblots showed a significant upregulation of mitochondrial content in R406 and tofacitinib-treated PSC-WAs and ADSC adipocytes (Fig. 6a) . To determine the impact of these changes on metabolic activity, oxygen consumption rate was measured. We found that basal, uncoupled and maximal respiration were increased when PSC-WAs and ADSC adipocytes were pre-treated for 7 days with tofacitinib or R406 as compared with a DMSO control (Fig. 6b) . Thermogenesis in brown adipocytes is fuelled by lipid catabolism, which can be measured by release of glycerol from fatty acid. We quantified the level of free glycerol from adipocyte culture medium and observed a ∼2.5-fold increase of basal lipolysis in tofacitinib-and R406-treated adipocytes (Fig. 6c) , but no significant increase in FSK-stimulated lipolysis (Fig. 6c) . Together, these data suggest the engagement of a brown-like metabolic program on inhibition of JAK-STAT in human adipocytes. 
JAK-inactivated adipocytes maintain a white adipocyte transcriptional identity
To determine whether tofacitinib and R406 treatment had converted the transcriptional identity of white adipocytes, we performed RNA-seq and analysed the whole transcriptome of MPCs, PSC-WAs, PSC-BAs and compound-treated PSC-WAs. We used multi-dimensional scaling to project expression data, where distances between samples reflect the differences between global gene expression profiles. As expected, PSC-WAs and PSC-BAs moved away from undifferentiated PSC-MPCs, and away from each other (Fig. 7a) . Despite the acquisition of a brown-like metabolic profile, tofacitinib-and R406-treated PSC-WAs global expression profiles clustered with untreated PSC-WAs samples and not with PSC-BAs (Fig. 7a) . Consistent with our findings, RNA-seq analyses revealed a strong induction of UCP1 expression by tofacitinib and R406 (Fig. 7b) . Among known positive regulators of brown adipogenesis, R406 promoted mRNA expression of PGC1α, PGC1β and PPARG (Supplementary Fig. 6 ). Intriguingly, PRDM16 mRNA expression was decreased in compound-treated PSC-WAs despite an increase at the protein level ( Supplementary Fig. 6 and Fig. 3 ). These data indicate that adipocyte browning by JAK inhibition occurs by functionally remodelling white adipocytes and through the acquisition of brown-like metabolic activities rather than through cell fate conversion.
Downregulation of IFN and activation of hedgehog signalling contribute to metabolic browning downstream of JAK inhibition
To decipher the molecular mechanisms underlying metabolic browning of adipocytes through JAK inhibition, gene set analyses were performed and enrichment scores calculated for 9,116 gene sets. Strikingly, all gene sets altered by tofacitinib were downregulated, most prominently interferon (IFN) response (IFNα/β/γ), STAT1/3/5 pathway and pro-inflammatory pathways (OSM and IRF; Fig. 7c) . Similarly, R406 largely attenuated IFN response and mediators of inflammation (OSM, TNF, chemokine) (Fig. 7c) . Tofacitiniband R406-treated adipocytes closely resembled one another in the differential expression profiles of IFN targets, of which 25 genes were nearly equally regulated by the two inhibitors (Fig. 7d,e) . IFNα/β/γ bind to JAKs and activate STAT1/2/3 (ref. 29) . Thus, the gene set enrichment score confirms our findings that tofacitinib and R406 inhibit the JAK-STAT pathway in adipocytes. The transcriptional changes downstream of R406 exhibited a broader spectrum of regulated gene sets in comparison with tofacitinib including upregulation of PPARG, SREBF and BMP target genes ( Fig. 7c and Supplementary Fig. 6 ), an observation in accordance with its positive effect on FABP4 expression (Fig. 3a) . We further interrogated RNA-seq data for individual genes upregulated in both tofacitinib-and R406-treated PSC-WAs. Fiftyfour genes were upregulated by both compounds, 17 of which were BAT-specific (Supplementary Fig. 6 ). Notably, we observed that GLI1 was upregulated in tofacitinib and R406-treated PSC-WAs and in PSC-BAs (Fig. 7f) . Moreover, three GLI1-target genes, SFRP5, KLHL31 and SHH, were upregulated, suggesting activation of sonic hedgehog (SHH) signalling downstream of JAK-STAT inhibition during adipocyte browning.
The common gene signature of tofacitinib-and R406-treated PSC-WAs suggests that inhibition of JAK-STAT signalling shortcircuits the IFN-JAK-STAT positive feedback loop and thereby progressively alleviates anti-browning and/or activates browning signals. We verified this hypothesis by inducing a white phenotype after addition of IFNγ to PSC-WAs, observable by the formation of unilocular lipid droplets, an effect that was reversed by addition of tofacitinib or R406 (Fig. 8a) . Moreover, IFNγ treatment of PSCWAs and PSC-BAs decreased the UCP1/FABP4 ratio and increased expression of the white adipocyte marker HSL (Fig. 8b) .
We observed that repression of IFN response was followed by upregulation of BA-specific transcripts in tofacitinib-and R406-treated PSC-WAs including the GLI1 transcription factor (Fig. 7f) . The previously reported antagonistic link between IFN and SHH (ref. 30 ) prompted us to evaluate the functional relevance of upregulation of GLI and GLI-target genes in tofacitinib-and R406-mediated metabolic browning. To examine the contribution of SHH signalling downstream of JAK-STAT inhibition during metabolic browning of adipocytes, PSC-WAs were subjected to increasing doses of cyclopamine, a SHH pathway inhibitor, in combination with DMSO, tofacitinib or R406 for 7 days. Addition of cyclopamine did not significantly alter gene expression in DMSO-treated PSCWAs but completely blocked tofacitinib-mediated induction of UCP1 expression (Fig. 8c) . Interestingly, high doses of cyclopamine antagonized the effect of R406 on UCP1 expression but did not block the induction of FABP4, thereby decoupling the regulation of UCP1 and FABP4 by R406 (Fig. 8c) . The upregulation of PPARG activity by R406 (Supplementary Fig. 6 ) probably accounts for this observation. UCP1 expression was also downregulated in PSC-BAs on treatment with cyclopamine ( Supplementary Fig. 7) . These results support a role for SHH signalling in the acquisition of brown-like properties in human adipocytes.
Overall, we provide evidence that inhibition of JAK downregulates interferon signalling in human adipocytes. The persistent repression of IFN signalling relieves inhibition of the SHH pathway 30 and thereby contributes to the upregulation of UCP1 and promotes the metabolic browning of adipocytes (Fig. 8d) .
DISCUSSION
The remarkable phenomenon of adipocyte browning-or the emergence of brown-like adipocytes in white adipose depots-and its associated metabolic benefits has spurred interest in the discovery of pharmacotherapies targeting adipose tissue to treat metabolic diseases such as obesity and type 2 diabetes. Here, we established a small-molecule screen to unravel pharmacologically accessible pathways capable of inducing a brown-like thermogenic program in human adipocytes. We identified tofacitinib and R406 as potent inducers of UCP1 and through secondary screening established their role in remodelling lipid droplet morphology in human adipocytes. We found that both compounds target the JAK-STAT1/3 pathway in adipocytes and have a distinct progressive and long-lasting effect that confers brown-like metabolic properties to white adipocytes. Our results further highlight important antagonistic interplays between interferon and sonic hedgehog signalling in adipocyte function.
Our findings are in line with previously proposed functions of Hedgehog in determining white versus brown adipose cell fate 31 . By using the Hedgehog activator Smoothened Agonist (SAG) in various mouse cell lines, the authors of the previous study showed that activation of Hedgehog blocks white, but not brown, adipocyte differentiation and solely in the absence of cAMP and glucocorticoid signalling. In our study, activation of Hedgehog signalling by JAK inhibition occurred in PPARG2-expressing cells in the presence of cAMP and glucocorticoid signalling and promoted the acquisition of a brown-like metabolic phenotype. It is thus conceivable that activation of Hedgehog signalling after adipogenesis is initiated and during the maturation of white adipocytes may promote the acquisition of brown-like properties. We further demonstrated that pharmacological inhibition of Hedgehog decreased UCP1 expression in genetically programmed BA and brown-like adipocytes. Interestingly, the authors of the previous study reported the upregulation of UCP1 mRNA levels in WAT and BAT tissue on genetic activation of Hedgehog in the aP2-SufuKO mouse, reminiscent of the data presented here on treatment with tofacitinib and R406. More recently, an antagonistic crosstalk between Hedgehog and IFNγ in white adipose tissue has been described, wherein inhibition of Hedgehog signalling by IFNγ rescues white adipocyte differentiation 30 . Our findings further reinforce and refine the role of an IFN-JAK-STAT-SHH axis in human adipocyte biology. A recent study revealed a positive role for Tyk2 and Stat3 in the regulation of Myf5 + pre-adipocyte differentiation and BAT development in mice 32 . In light of our findings, it will be interesting to investigate the role of TYK2-STAT3 and other JAK-STATs in committed, functional brown adipocytes. A fine-tuning of the JAK-STAT pathway at various stages of differentiation and maturation might be key for optimum BAT expansion and metabolic function.
The utility of JAK inhibition as a therapeutic strategy for obesity is complicated by the well-described role of this signalling pathway in the immune system. In fact, tofacitinib is approved in the United States to treat rheumatoid arthritis. Thus, if one were to imagine targeting adipose tissue by in vivo administration of an IFN-JAK-STAT inhibitor or similar compound it would almost certainly need to be delivered locally and prevented from spreading systemically or alternatively targeted selectively to white adipocytes. One could also conceive of a cell-based therapy wherein JAK inhibition of patient-derived adipocytes ex vivo is followed by transplantation to treat obesity, but this therapeutic modality would need to overcome numerous and significant obstacles before becoming a reality. A further limitation of the current study is the lack of evidence that JAK inhibition would promote metabolic browning in vivo, in particular in humans where evidence supporting this phenomenon is scant. Thus, additional research is required before inhibition of IFN-JAK-STAT signalling could be used therapeutically for the treatment of metabolic disorders.
Recent progress in the development of human embryonic stem cells and induced PSC-based models of disease have delivered unprecedented tools for basic research and translational medicine. However, their applicability for drug discovery remains to be fully realized. Here, we tested the suitability of a human PSC-derived adipocyte model 15 for screening and functional browning assays. We found this model provided an inexhaustible and rapidly expandable source of human adipocytes for screening and downstream assays. Moreover, it proved easily scalable and highly reliable in our screening assay. The responsiveness of human PSC-derived adipocytes to known and newly identified browning molecules closely mirrored that of ADSC-derived adipocytes, further validating this model for adipocyte cell fate and browning studies.
To conclude, we successfully performed a proof of concept screen using an innovative stem-cell-based model to identify compounds that convert human adipocytes to metabolically active brown-like cells. Given that this platform is amenable to very high-throughput screening it has considerable potential to contribute to the discovery of new biological modulators of adipocyte cell fate and function and possibly to the development of new drugs for patients with metabolic disorders.
METHODS
Methods and any associated references are available in the online version of the paper. were generated and differentiated as described previously 15 with the following modifications: MPCs were derived from human embryonic stem cell line SA001 (Cellartis), and were seeded at 75% confluency in 15 cm dishes, incubated overnight with lentiviral particles at an MOI of 50 for each virus and maintained in growth medium without virus for 24 h. Infected MPCs (herein PPARG2-MPCs) were counted and seeded in 96-well plates at a density of 37,500 cells cm −2 in growth medium. The next day (Day 0), growth medium was changed for induction medium consisting of adipocyte medium (DMEM, Knockout Replacement Serum, non-essential amino acids, insulin, dexamethasone) supplemented with 700 ng ml −1 doxycycline and 0.5 µM rosiglitazone. Seventy-two hours later (Day 3), induction medium was replaced by differentiation medium (adipocyte medium supplemented with 700 ng ml −1 doxycycline) for 96 h. From day 7, white (PSC-WAs) and brown (PSC-BAs) adipocytes were maintained in adipocyte medium and refreshed every two or three days.
Adipose tissue-derived stromal cells (ADSCs) were obtained from PromoCell (human mesenchymal stem cell from adipose tissue or hMSC-AT, catalogue number C-12977) and maintained in mesenchymal stem cell growth medium (PromoCell C-28010) according to the manufacturer's instructions. For differentiation studies, ADSCs were seeded in 96-well plates at a density of 37,500 cells cm −2 . At 90% confluency, growth medium was changed for adipogenic differentiation medium (PromoCell C-28011) and refreshed every third day.
Compound library for adipocyte browning screen. A library of 867 small molecules of known mode of action was assembled by combining Roche internal reference compounds and commercially available screening libraries (Tocriscreen Collections no. 3514 Kinase inhibitor toolbox, Selleckchem Stem cell no. L2100, Selleckchem Epigenetic no. L1900 and Selleckchem GPCR no. L2200). All compounds were pre-dissolved in DMSO, diluted to 5 mM stock solutions and stored at −80 • C. A list of compound IDs, modes of action and CAS numbers is available on request.
Browning screen, statistical analysis and hit validation. PPARG2-MPCs were seeded in 96-well plates, induced and differentiated into PSC-WAs as described above. A library of small molecules was applied at a 5 µM final concentration in biological duplicates at day 7, 10 and 12 in fresh adipogenic medium. DMSO and rosiglitazone (0.5 µM final concentration) were included on each plate as negative and positive controls respectively. Adipocytes were collected at day 14 and processed for UCP1 and FABP4 mRNA analysis by bDNA.
For statistical analysis, the raw mRNA signal was log-transformed and normalized to fold-change of the per plate median of the negative controls for all calculations, x norm = log(s raw )/M neg , where M neg = median plate {log(s neg )}. The data quality was assessed by calculating the Z factor based on positive and negative controls for each plate (Supplementary Fig. 1b ). For UCP1, Z = 0.50, and Z >0.50 for 11 out of 24 plates; for FABP4, Z = 0.64, and Z > 0.50 for 18 out of 24 plates. This is characteristic for a good-quality HCS (ref. 33) . To evaluate the reproducibility of compound effect, biological duplicates were aggregated to their mean; 5% of the compounds were excluded from further analysis because their UCP1 difference was larger than 0.07; Supplementary Fig. 1c shows that the replicate difference distribution is constant over the entire range, suggesting a constant replicate variance.
The remaining 832 compounds were used for hit selection as described before 34 . Knowing the constant variance from the controls, a P value could be assigned to each compound following the test statistics T = (x norm − 1)/σ neg , where σ neg = MAD plate {log(s neg )}, which is normal distributed for inactive compounds (that is, under the null hypothesis H 0 ). We next estimated the false discovery rate (FDR) by P-value distribution analysis 35 and applied a selection threshold of <0.01. Supplementary Fig. 1d , left panel, illustrates the selected primary actives among the non-selected compounds in a quantile-quantile plot and the P-value distribution (inset). Next, a second hit selection process for FABP4 was included, again at a FDR cutoff <0.01 ( Supplementary Fig. 1d, right panel) . We thereby found 135 UCP1 hits, of which 52 were assigned as 'rosiglitazone-like' compounds that induced both UCP1 and FABP4. In the validation experiment, we selected browning hits that induced UCP1 by at least twofold and UCP1/FABP4 by at least 1.5-fold. PPAR agonists were also included for a total of 33 re-tested compounds, of which 26 were confirmed ( Supplementary Fig. 1d, left panel) . Fifteen validated hits and PPAR agonists are shown in Fig. 1d and chemical names are provided in Supplementary Table 1 .
High-content imaging. At day 14 of the browning assay, cells were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature, incubated with blocking buffer (5% donkey serum, 0.5% Triton X-100 and 0.02% azide NaN 3 in PBS) for 30 min at room temperature and stained with 10 µM Hoechst (B2261, Sigma) and 20 ng ml −1 of Bodipy 493/503 (D-3922, Life Technologies) in PBS for 30 min at room temperature. Samples were kept in PBS. Fluorescence images were acquired using the Opera QEHS reader (Perkin-Elmer) equipped with a Nipkow spinning disc for confocality using a ×20 objective. Hoechst stain was imaged with laser excitation at 405 nm and a 455/70 nm band-path filter for emission. The lipid stain was imaged using laser excitation at 488 nm, and a 535/60 nm/BP filter for emission. The image segmentation was done with the instrument-integrated software Acapella. A custom-made algorithm was used to identify the morphologically heterologous nuclei in the mixed cell population: larger, round and relatively dark (brown adipocytes, non-differentiated cells); smaller, bright, more irregular-shaped nuclei (white). The lipid droplets were segmented independently as either larger round bright objects or darker spots and assigned to individual nuclei on the basis of an equidistant ring around the nuclei. The ratio in the total area of cell-related droplets above and below 1,070 µm 2 was quantified as the shift between a more white and brown phenotype in the whole cell population. Cell classification: adipocyte, total droplet area above 750 µm 2 and/or >10 spots <50 µm 2 ; white subtype, minimum one droplet above 830 µm 2 ; brown subtype, no larger droplets, minimum 10 spots.
Browning assay with tofacitinib, R406, JAK inhibitors and BMP7. Following screening and hit validation, browning assays were performed with commercially available JAK3 inhibitor (tofacitinib, Selleckchem S5001) and SYK inhibitor (R406, Selleckchem S1533). PSC-WAs and ADSCs were differentiated and treated following the assay design of the browning screen. Tofacitinib was added at 2 µM and R406 at 1 µM final concentration unless otherwise indicated in the figures and legends. THRB agonist (CAS 219691-94-8) was added at 5 µM final concentration. Ruxolitinib (Selleckchem S1378), baricitinib (Selleckchem S2851), CYT387 (Selleckchem S2219) and AZD1480 (Selleckchem S2162) were added at 0.1-5 µM final concentration as indicated in the figures. Recombinant human BMP7 (R&D systems, 354-BP) was added at 10 ng ml −1 final concentration in adipogenic medium supplemented with 250 µM IBMX (3-isobutyl-1-methylxanthine, Sigma-Aldrich I7018) at day 0, 3 and 5. In ADSCs, BMP7 was added at 10 ng ml −1 at day 7, 10 and 12. Tofacitinib and R406 were added following the same conditions as BMP7 for proper comparison.
Browning of mouse adipose tissue explants. Subcutaneous and visceral adipose depots were dissected from 8-week-old male C57/Bl6 mice (n = 5) and minced in standard media (DMEM containing 10% FBS and 1% penicillin/streptomycin). Minced pieces were pooled, placed into a 100 µM nylon strainer and rinsed 3 times with standard media to remove red blood cells and excess lipid. Explants were carefully removed from the top of the strainer and plated into 24-well plates. Following 48 hours of acclimatization in adipogenic medium (DMEM, 10% FBS, 1% penicillin/streptomycin, 17 nM insulin, 1 µM dexamethasone) cells were treated with adipogenic medium containing DMSO, tofacitinib or R406 at 1, 2 and 5 µM final concentrations. Each treatment was performed in triplicate. Medium with fresh compound was replaced every other day. Following 7 days of treatments, RNA was extracted in Trizol (Life Technologies) following a standard protocol. Reverse transcription was performed using Superscript III (Life Technologies) followed by analysis on a ViiA7 Real-Time PCR System (Life Technologies). Expression was analysed relative to 18s RNA levels. Taqman probes were purchased from Life Technologies (UCP1: catalogue number Mm01244861_m1, 18S: catalogue number Mm03928990_g1).
Treatment with TNFα, INFγ and cyclopamine. TNFα (human recombinant tumour necrosis factor alpha, Sigma-Aldrich T0157) was added directly to cell medium 48 h or 24 h before the end of the assay, at a final concentration of 0.25 ng ml −1 or 1 ng ml −1 respectively. IFNγ (human recombinant interferongamma, Sigma-Aldrich I3265) and cyclopamine (Tocris, 1623) were added to fresh cell medium containing DMSO, tofacitinib or R406, at day 7, 10 and 12. For all treatments, a corresponding volume of solvent (PBS, DMSO or ethanol, according to the supplier's recommendation) was added to control wells and used for normalization.
Gene expression analysis by branched DNA (bDNA). Adipocytes grown in 96-well plates were collected by replacing adipocyte medium with 100 µl per well of 1x RNA lysis mixture (Panomics QuantiGene2.0 Assay kit). Lysates were transferred to mRNA capture plates containing a specific capture probe (Supplementary Table 2 ), incubated overnight, processed for bDNA amplification and analysed according to the manufacturer's instructions (Panomics QuantiGene2.0 Assay). ACTB and PPIB probes were used as housekeeping genes for normalization. Data are presented as average and standard deviation of 2 or 3 biological replicates and normalized on DMSO control.
Western blot analysis. For protein analysis, browning assays were performed in 6-well plates initially seeded with 5 × 10 5 PPARG2-MPCs. At differentiation Table 1 . Validated browning hits and PPAR agonists shown in Figure 1D . Table 1 Validated browning hits and PPAR agonists shown in Figure 1D . 
